During this segment, the panelists explore newer therapeutic agents that are now receiving a lot of attention in the healthcare market for the management of cardiovascular health, and discuss which products have the greatest potential when treating cardiometabolic events.
David Calabrese, RPh, MHP, discusses the large number of late-phase agents that are available to treat diabetes and believes that product variety allows clinicians to tailor treatment specifically to the patient.
Additionally, Kenneth L. Schaecher, MD, FACP, CPC, discusses the potential of vaccine therapy and gene therapy, which are currently being studied for the treatment of type 1 diabetes.
Yehuda Handelsman, MD, FACP, FACE, FNLA, concludes the discussion by summarizing the most promising products available to treat other cardiometabolic events such as lipid disorders and obesity.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More